Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks

AIDS Patient Care and STDs

Volumn 25, Issue 6, 2011, Pages 333-340

  Currier, Judith S ^a,f   Martorell, Claudia ^b   Osiyemi, Olayemi ^c   Yin, Michael T ^d   Ryan, Robert ^e   De La Rosa, Guy ^e   Mrus, Joseph ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Research Institute   (United States)

^c Triple O Medical Services Inc   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e Tibotec Inc   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; GLUCOSE; INSULIN; LIPID;

ANTHROPOMETRIC PARAMETERS; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PATIENT COMPLIANCE; PATIENT SATISFACTION; RACE DIFFERENCE; SELF CONCEPT; SEX DIFFERENCE;

ADULT; BLOOD GLUCOSE; BODY IMAGE; BODY SIZE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INSULIN; LIPIDS; MALE; MIDDLE AGED; RITONAVIR; SEX FACTORS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 79957595718     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2010.0386     Document Type: Article

References (20)

1. Walmsley S, Cheung AM, Fantus G, et al. A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy. HIV Clin Trials 2008;9:314-323.
2. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch Intern Med 2000;160:2050-2056. (Pubitemid 30437589)
3. Hill A, Sawyer W, Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials 2009;10:1-12.
4. Absalon J, Uy J, Rong Y, Mancini M, McGrath D. Genderbased differences in ARV-naive patients treated with boosted protease inhibitors (PIs): Results from the CASTLE study (AI424138) [Abstract TUPE0062]. Poster presented at the 17th International AIDS Conference, Mexico City, Mexico, August 3-8, 2008.
5. Hoffman RM, Umeh OC, Garris C, Givens N, Currier JS. Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials 2007;8:371-380. (Pubitemid 350305211)
6. Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/ nelfinavir on lipids, metabolic parameters and efficacy in antiretroviralnaive patients: Effect of sex and ethnicity. HIV Med 2006;7:85-98.
7. Thiebaut R, Dequae-Merchadou L, Ekouevi DK, et al. Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: The Aquitaine Cohort, France, 1996-99. HIV Med 2001;2:84-88. (Pubitemid 33114745)
8. Evelyn B, Toigo T, Banks D, et al. Women's participation in clinical trials and gender-related labeling: A review of new molecular entities approved 1995-1999. USDA, June 2001. www.fda.gov/ForConsumers/ByAudience/ ForPatientAdvocates/ParticipatinginClinicalTrials/ucm197788.htm. (Last accessed January 25, 2011).
9. Zorrilla C, Agrait V. Why do we need the GRACE (Gender, Race, And Clinical Experience) study? Future HIV Ther 2007;1:357-363.
10. Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: A single-group trial. Ann Intern Med 2010;153:349-357.
11. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009;23: 1679-1688.
12. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. NIH Publication No. 02-5215. September 2002.
13. Currier J, Scherzer R, Bacchetti P, et al. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr 2008;48:35-43. (Pubitemid 351600850)
14. Wohl D, Scherzer R, Heymsfield S, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008;48: 44-52. (Pubitemid 351600858)
15. Loutfy M, Andany N, Li M, et al. Gender and ethnicity differences in body change and distress of HIV-positive individuals taking antiretroviral therapy in Ontario [Poster P- 08]. Antivir Ther 2009;14:A29.
16. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 2003; 34:58-61. (Pubitemid 37100112)
17. Wilson ME, Allred KF, Kordik EM, Jasper DK, Rosewell AN, Bisotti AJ. Gender-specific effects of HIV protease inhibitors on body mass in mice. AIDS Res Ther 2007;4:8.
18. Plankey M, Bacchetti P, Jin C, et al. Self-perception of body fat changes and HAART adherence in the Women's Interagency HIV Study. AIDS Behav 2009;13:53-59.
19. Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIVinfected population: It all depends on the definition. HIV Med 2001;2:174-180. (Pubitemid 33114761)
20. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493-2505. (Pubitemid 30038027)